secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2024-06-06T23:59:59+00:00
Accession:  0001140361-24-029050
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio reports positive Phase 2 infigratinib results in achondroplasia; initiates hypochondroplasia study
--------------------------------------------------------------------------------

- Cohort 5 (0.25 mg/kg/day) showed sustained AHV increase: +2.51 cm/yr at Month 12, +2.50 cm/yr at Month 18 (p=0.0015).
- Statistically significant improvement in body proportionality: upper/lower segment ratio 1.88 at Month 18 vs 2.02 baseline (p=0.001).
- No treatment-related adverse events in Cohort 5; drug well-tolerated as single daily oral therapy.
- First child consented in ACCEL observational study for hypochondroplasia; Phase 2/3 interventional study planned.
- PROPEL 3 Phase 3 registrational enrollment on schedule, completion estimated by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036124029050/0001140361-24-029050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036124029050/ef20030678_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-029050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer